Equities analysts forecast that Protagonist Therapeutics Inc (NASDAQ:PTGX) will post earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Protagonist Therapeutics’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.69). Protagonist Therapeutics reported earnings of ($0.29) per share during the same quarter last year, which would suggest a negative year over year growth rate of 41.4%. The firm is expected to issue its next earnings report on Monday, November 5th.

On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($0.73). For the next fiscal year, analysts forecast that the business will report earnings of ($1.75) per share, with EPS estimates ranging from ($2.20) to ($1.29). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07). Protagonist Therapeutics had a negative return on equity of 24.16% and a negative net margin of 56.92%. The firm had revenue of $11.67 million during the quarter, compared to the consensus estimate of $8.55 million.

PTGX has been the subject of a number of recent research reports. Barclays cut Protagonist Therapeutics from an “overweight” rating to an “equal weight” rating and set a $18.00 target price for the company. in a report on Wednesday, June 6th. Leerink Swann lifted their target price on Protagonist Therapeutics from $13.00 to $21.00 and gave the stock an “outperform” rating in a report on Monday, August 6th. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $22.00.

NASDAQ:PTGX opened at $8.88 on Thursday. The company has a market capitalization of $213.64 million, a price-to-earnings ratio of -4.25 and a beta of 3.75. Protagonist Therapeutics has a 1 year low of $5.50 and a 1 year high of $23.97.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in Protagonist Therapeutics during the 1st quarter valued at $1,227,000. Prudential Financial Inc. bought a new stake in Protagonist Therapeutics during the 1st quarter valued at $116,000. Schwab Charles Investment Management Inc. raised its position in Protagonist Therapeutics by 67.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,315 shares of the company’s stock valued at $278,000 after purchasing an additional 13,015 shares in the last quarter. BlackRock Inc. raised its position in Protagonist Therapeutics by 39.0% during the 1st quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock valued at $5,904,000 after purchasing an additional 192,632 shares in the last quarter. Finally, Federated Investors Inc. PA raised its position in Protagonist Therapeutics by 266.8% during the 1st quarter. Federated Investors Inc. PA now owns 63,921 shares of the company’s stock valued at $549,000 after purchasing an additional 46,496 shares in the last quarter. Institutional investors own 57.93% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Recommended Story: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.